// App-Quantinova.ai

e16542 : Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.

Researchers

Presenter

  • Chung-Han Lee

Principal Investigators

  • Amishi Yogesh Shah

  • James J Hsieh

  • Arpit Rao

  • Alvaro Pinto

  • Mehmet Asim Bilen

  • Allen Lee Cohn

  • Christopher DiSimone

  • David R. Shaffer

  • Regina Girons Sarri

  • Sara Gunnestad Ribe

  • Jane Wu

  • Emmett V. Schmidt

  • Peter Kubiak

  • Chinyere Okpara

  • Alan D. Smith

  • Robert J. Motzer

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Breast Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX

  • Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.

  • Department of Clinical Research, South Texas Accelerated Research Therapeutics, San Antonio, TX

  • Servicio de Medicina Nuclear, Hospital Universitario La Pax, Madrid, Spain

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA

  • Medical Oncology, US Oncology Research, Rocky Mountain Cancer Center, Denver, CO

  • Medical Oncology/Hematology, Arizona Oncology Associates, Tucson, AZ

  • Medical Oncology, US Oncology Research, New York Oncology Hematology, Albany, NY

  • Clinical Pathology Service,Hospital Universitari i Politècnic La Fe,Valencia,Spain

  • Medical Oncology, Sorlandet Hospital Kristiansand, Kristiansand, Norway

  • Biostatistics, Eisai Inc., Woodcliff Lake, NJ

  • Clinical Research, Merck & Co., Inc., Kenilworth, NJ, USA

  • Clinical Research, Eisai Inc., Woodcliff Lake, NJ

  • Clinical Research, Eisai Ltd., Hatfield, United Kingdom

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

Locations

  • United States

  • Spain

  • Norway

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT02501096

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved